PRIMA-SOLUTIONS
24.9.2018 10:02:12 CEST | Business Wire | Press release
As part of its continuing growth strategy, Prima Solutions (Prima), the premier software platform for Property and Casualty insurers, has agreed to acquire ICOD Inc. (ICOD), the Canadian provider of software solutions for Life and Health insurance. Recognized as an established leader with its SN Assurance suite, ICOD offers a best-in class solution deliverable in SaaS or on premise.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180924005019/en/
The transaction, which closed on September 20th, accelerates Prima’s expansion into the Life and Health insurance market which is still largely using legacy technologies. The ICOD acquisition offers many synergies including: complementing Prima’s existing product offering, diversifying its customer base and expanding the platform for rapid growth in both Europe and North America.
Hugues Delannoy, Chairman of Prima Solutions, said: "This acquisition provides a unique opportunity to accelerate our growth strategy and gain scale both in France and internationally. The transaction offers immediate synergies and reinforces our plan to diversify our product offering to take advantage of the fast growing demand in the Life and Health insurance segment for a modern scalable platform .”
Pascal Gosset, Founding President of ICOD Inc., added: "Having already worked closely together with Prima on several occasions, our shared vision has led us to join forces to position ourselves as one of the strategic technology providers in the Property and Casualty and the Life and Health insurance markets. The combination of both organizations will allow clients continue to benefit from the same high level of quality service and expertise while also gaining access to increased product offerings through a single software provider ".
About Prima Solutions
Prima Solutions provides Property and
Casualty insurers the cutting-edge Prima Insure™ software platform to
increase agility and become a leader in insurance innovation. 100
percent web enabled, modular, multilingual and delivered via SaaS mode,
Prima Insure™ addresses the entire life cycle of an insurance policy:
distribution; underwriting; contract; claims, financial management and
predictive analytics. More than 67 Property and Casualty insurers have
already chosen to innovate with Prima Insure™. Prima Solutions is a
member of ACORD.
Web
www.prima-solutions.com
| Twitter
https://twitter.com/Prima_Solutions
About ICOD
Founded in 2000 in Montreal ICOD delivers the
software platform Life and Health insurers need to gain in agility and
efficiency in a highly competitive market. Full web, modular,
multilingual and available in SaaS mode, ICOD’s software platform
addresses the whole life cycle of an insurance policy: distribution;
underwriting; contract management; claims and financial management. More
than 10 Life and Health insurers have selected ICOD’s software platform
to manage their activities end-to-end. ICOD employs 55 professionals
worldwide, and its employees will become part of the Prima Solutions
group in the context of this transaction.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180924005019/en/
Contact:
MEDIA Prima Solutions Frédéric DUTREUIL, +33(0)1-70-91-13-16 / +33(0)6-24-04-23-39 frederic.dutreuil@prima-solutions.com or Leslie MADUBOST, +33(0)1-70-91-24-78 leslie.madubost@prima-solutions.com or Steele&Holt Daphne CLAUDE & Dominic RIDING, +33(0)6-66-58-81-92 / +33(0)6-57-48-83-24 carlyle@steeleandholt.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom